9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 104 of the 106 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While generally well tolerated, an increased risk of HHF was found with saxagliptin, which is re fl ected in its label, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4i class (16).”
In the citing paper
“Current treatment protocols propose considering weight impact when choosing diabetes treatment strategies, and GLP-1RAs have shown a notably positive therapeutic profile for overweight or obese individuals with T2DM. 78”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [78]
In the citing paper
“Currently, these guidelines recommend SGLT2is and GLP-1RAs as the preferred therapy among individuals with type 2 diabetes and comorbid ASCVD or HF, and SGLT2is among those with comorbid CKD [8, 9].”
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [147]
In the citing paper
“Based on evidence from large cardiovascular outcomes trials, the latest professional society guidelines continue to recommend sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for patients with type 2 diabetes (T2D) and established cardiovascular disease (CVD).1,2”
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Metformin is effective and safe, is inexpensive, and may reduce risk of cardiovascular events and death (45).”
BackgroundIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“The ADA/EASD consensus report “Management of Hyperglycemia in Type 2 Diabetes, 2018” and the 2019 update (43,44) recommend a patient-centered approach to choosing appropriate pharmacologic treatment of blood glucose.”
BackgroundRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M. B., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 965
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Holt, R. I. G., DeVries, J. H., Hess-Fischl, A., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, E., et al. (2021) · Diabetes Care · doi:10.2337/dci21-0043 · Cited by 699
Research works printed but not linked: 2
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Vaz, 2018, Effectiveness and safety of carbohydrate counting in the management of adult patients with type 1 diabetes mellitus: a systematic review and meta-analysis, Arch Endocrinol Metab, 62, 337
Cited by
Items 701–800 of 1,000
Swift, C., Frazer, M., Gronroos, N. N., Sargent, A., Leszko, M., Buysman, E. K., Alvarez, S., Dunn, T. J., Noone, J. M., & Guevarra, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15516 · Cited by 7
SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses
March, K. L., Lukas, J. G., Berei, T. J., Shah, S. P., & Cave, B. E. (2022) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000401 · Cited by 7
Hayes, K. N., Berry, S. D., Munshi, M. N., & Zullo, A. R. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18360 · Cited by 7
Gazzaruso, C., Coppola, A., Montalcini, T., & Falcone, C. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.30 · Cited by 7
Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era
Krentz, A. J., & CHILTON, R. J. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000150 · Cited by 7
GLP-1RAs for the treatment of obesity in women after menopause
Paschou, S. Α., Kotsa, K., Peppa, Μ., Hatziagelaki, E. E., & Ψαλτοπούλου, Θ. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.12.003 · Cited by 8
Zhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v1 · Cited by 7
Kolkailah, A. A., Lingvay, I., Dobrecky‐Mery, I., Aharonovich, A., David, J., Holse, C., Rasmussen, S., & McGuire, D. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14941 · Cited by 6
“The findings also support the broad endorsement for prioritized use across society recommendations and guidelines.(1,2,6,7) Complementing the findings of reduction in incident coronary events, the effect on total events of the primary and expanded coronary out-”
BackgroundSolanki, A., Kamrava, M. R., Posadas, E. M., Freedland, S. J., Ballas, L., Sandler, H. M., Merz, C. N. B., Atkins, K. M., & Nikolova, A. (2024) · Cancer · doi:10.1002/cncr.35285 · Cited by 8
Bramlage, P., Vijayan, A., Varghese, T. P., Sadanandan, D. M., Lanzinger, S., & Rodriguez, C. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70010 · Cited by 7
Choi, J. H., Kang, S., Kim, S., Kim, W. J., Kim, J. M., Bae, J., Yun, J., Jeon, E. J., Kim, Y., Bae, J. H., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0978 · Cited by 10
“The usual starting total daily insulin dose is 0.4–0.5 units/kg, administered as approximately 50% basal and 50% divided among prandial doses before meals [39].”
InfluentialCastellano, E., Borretta, G., Attanasio, R., Boriano, A., Agrimi, D., Argese, N., Crescenti, C., Disoteo, O., Fusco, A., Gabellieri, E., et al. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666221115091621 · Cited by 6
Kim, H. C., Lee, S., Sung, S., Kim, E., Jang, I., & Chung, J. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s404182 · Cited by 6
Kulesh, A. A., Yanishevskiy, S. N., Demin, D. A., Syromyatnikova, L. I., & Vinogradov, O. I. (2023) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2023-3-4-10 · Cited by 6
Tancredi, M., Chrusciel, J., Zaouia, S., Mergey, V., Laplanche, D., & Sanchez, S. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11726-1 · Cited by 6
“The management of this condition is to optimize blood glucose levels through a multidisciplinary approach primarily based on lifestyle modifications (such as food intake and physical activity) [10, 11], with the possible addition of an insulin treatment [12].”
BackgroundGlucagon-like Peptide-1 Receptor Agonists in the Management of Diabetic Retinopathy
Samanta, A., Bordbar, D. D., Weng, C. Y., & Chancellor, J. R. (2024) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000541 · Cited by 7
“14,15 Third-generation semaglu-tide iterates on prior drugs of the same pathway with an extended half-life enabling weekly subcutaneous dosing intervals.”
Saedi, S., Tan, Y., Watson, S. E., Sparks, J. D., Wintergerst, K. A., & Cai, L. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00673.2024 · Cited by 9
“A variety of antidiabetic drugs are currently available for adult patients that can improve blood glucose levels, prevent acute and chronic diabetes complications, improve insulin sensitivity, and improve endogenous insulin release and glucagon and incretin physiology (194, 196).”
Cai, L., Zhao, Y., Li, Z., Xiao, L., Wu, Y., Wang, S., Liu, Q., Ye, Y., Guo, Y., & Zhang, D. (2025) · Advanced Science · doi:10.1002/advs.202503173 · Cited by 10
Managing the Burden of Dementia-Related Delusions and Hallucinations
Small (2020) · The Journal of Family Practice · doi:10.12788/jfp.0065 · Cited by 6
Talbo, M. K., RABASA-LHORET, R. P. R., Yale, J., Peters, T. M., & Brazeau, A. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110080 · Cited by 8
Assaad-Khalil, S. H., Elkafrawy, N., Khaled, M., Mogeib, O., Badr, H. R., Rashwan, A., Youssef, M., Eltamawy, K., & Mohamed, S. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9176026 · Cited by 7
Zhu, J., Wang, H., Huang, S., Zhang, Y., Liu, X., Li, Y., & Ma, J. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1034004 · Cited by 5
Jeong, S. I., Kim, Y., Nah, J. J., Huh, W., Jang, I., Hwang, J. G., & Lee, S. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15632 · Cited by 6
Banjara, B., Poudel, N., Garza, K. B., Westrick, S. C., Whitley, H. P., Redden, D. T., & Ngorsuraches, S. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s391719 · Cited by 6
Cost and value in liver disease guidelines: 2011–2022
Aby, E. S., Kaplan, A. J., & Ufere, N. N. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000001 · Cited by 6
“For example, the American Diabetes Association CGD on pharmacologic management for glycemic treatment reports the median monthly costs for glucose-lowering agents.[15] For physicians, it is important to keep in mind that the cost of medications can also exacerbate disparities.”
BackgroundDagogo-Jack, S. E., Frederich, R. C., Liu, J., Cannon, C. P., Shi, H. H., Cherney, D. Z. I., Cosentino, F., MASIUKIEWICZ, U. S., Gantz, I., & Pratley, R. E. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac764 · Cited by 6
Panchal, R., Nguyen, D. T., Ghule, P., Li, N., Giannouchos, T. V., Pan, R. J., BISKUPIAK, J. E., Britton, L., Nohavec, R., Slager, S. L., et al. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.2.139 · Cited by 7
Lü, B., Sun, J., Chen, L., Song, X., Deng, Y., Dong, Y., Dong, J., Du, P., Ge, J., Guo, Y., et al. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.01.003 · Cited by 7
Liu, J., Su, S., Kuo, F.-C., Li, P., Huang, C., Ho, L.-J., Chen, K.-C., Liu, Y.-C., Lin, C.-P., Cheng, A.-C., et al. (2023) · Medicine · doi:10.1097/md.0000000000033167 · Cited by 6
Chan, J. S. K., Perone, F., Bayatpoor, Y., Tse, G., & Harky, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2204188 · Cited by 7
Pulleyblank, R., & Larsen, N. B. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00416-z · Cited by 7
Schapiro, D., Juneja, R., Huang, A., Meeks, A., Liu, D., Gelsey, F. T., & Perez‐Nieves, M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01414-4 · Cited by 7
Hollander, P. A., Krause-Steinrauf, H. J., Butera, N. M., Kazemi, E. J., Ahmann, A., Fattaleh, B. N., Johnson, M. L., Killean, T., Lagari, V. S., Larkin, M., et al. (2023) · Diabetes Care · doi:10.2337/dc23-0516 · Cited by 6
Impact of Aging and Cellular Senescence in the Pathophysiology of Preeclampsia
Suvakov, S. R., Kattah, A. G., Gojković, T., Enninga, E. A. L., Pruett, J. E., Jayachandran, M., Sousa, C., Santos, J., Hassan, C. A., Suarez, M. L. G., et al. (2023) · Comprehensive physiology · doi:10.1002/cphy.c230003 · Cited by 6
Xu, M., Sun, K., Xu, W., Wang, C., Yan, D., Li, S., Cong, L., Pi, Y., Song, W., Sun, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03089-x · Cited by 6
Zamanillo‐Campos, R., Fiol-deRoque, M. A., Serrano-Ripoll, M. J., Mira-Martínez, S., Cànaves, J. L., Taltavull-Aparicio, J. M., Leiva, A., Ripoll-Amengual, J., Angullo-Martínez, E., Socias, I. M., et al. (2023) · Contemporary Clinical Trials · doi:10.1016/j.cct.2023.107399 · Cited by 6
Irace, C., Acmet, E., Cutruzzolà, A., Parise, M., Ponzani, P., Scarpitta, A. M., & Candido, R. (2023) · Endocrine · doi:10.1007/s12020-023-03605-2 · Cited by 6
“The utility of SMBG in daily life is evident in insulin-treated patients with type 1 (T1D) and type 2 diabetes (T2D) [1].”
BackgroundSamuels, S. L., Chajecki, A., Hu, P., Kayser, M., Weyman, K., Pan, B., Brown, E. A., Name, M. A. V., & Wolf, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15430 · Cited by 6
“26 Interestingly, these findings were different compared with the trials of once-weekly and daily GLP-1RA in youth with T2D where there were no statistically significant changes in BMI-Z compared with placebo at 6 months.”
BackgroundAtsarina, D. M., Widyastiti, N. S., Muniroh, M., Susilaningsih, N., & Maharani, N. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23080 · Cited by 6
“8 Metformin remains the first-line therapy for patients diagnosed with T2DM 10 and has proven effective in preventing the onset of T2DM in high-risk individuals.”
BackgroundInfluentialLv, L., Wang, Y., Xie, L., Noone, J. M., Alvarez, S., Zhang, Y., Song, Y., & Rotroff, D. M. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.018 · Cited by 6
Lingow, S. E., & Guyton, J. E. (2020) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2020.02.028 · Cited by 6
Chen, H., Hsieh, M., Ho, C.-W., Chen, C., Hsu, S.-P., Lin, C., & Kao, C. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-278 · Cited by 6
Seger, C. D., Xing, H., Wang, L., & Shin, J. S. (2021) · A&A Practice · doi:10.1213/xaa.0000000000001380 · Cited by 6
Rifai, M. A., Vaughan, E. M., Abushamat, L. A., Lee, M., Ramsey, D. J., Gupta, K., Navaneethan, S. D., & Virani, S. S. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.02.013 · Cited by 6
Naïditch, N., Mauchant, C., Benabbad, I., Hehn, C., Joubert, M., Thébaut, J.-F., & Rosilio, M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01337-6 · Cited by 7
Racial and Ethnic Disparities in Diabetes Clinical Care and Management: A Narrative Review
Young, C., & Myers, A. K. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.11.013 · Cited by 7
Effects of a New Group of Antidiabetic Drugs in Metabolic Diseases
Sanz‐Cánovas, J., Ricci, M., Cobos-Palacios, L., Sampalo, A. L., Hernández-Negrín, H., Vázquez-Márquez, M., Mancebo-Sevilla, J. J., Álvarez-Recio, E., Lopez-Carmona, M. D., Velasco, M. Á. P., et al. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2402036 · Cited by 6
Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report
Klinkner, G., & Steingraber-Pharr, M. (2023) · AACN Advanced Critical Care · doi:10.4037/aacnacc2023830 · Cited by 6
Alawainati, M., Ayoob, Z. A., AlQari, A. A., Makhlooq, F., Naser, H. S., & Bukamal, F. (2023) · Journal of Family and Community Medicine · doi:10.4103/jfcm.jfcm_9_23 · Cited by 7
Results of semaglutide in patients older than 70 years, a real-world study of efficacy and safety
de Lucas, M. D. G., Perez-Belmonte, L. M., Avilés, B., Jiménez-Millán, A., Rivas‐Ruiz, F., & Miramontes‐González, J. P. (2023) · Minerva Endocrinology · doi:10.23736/s2724-6507.23.03985-4 · Cited by 8
Bashier, A. M., Farghaly, M., Ali, J. A., Alhadari, A. K., Ajaz, Y., Warrier, V. K., Abdelgadir, E., Farooqi, M. H., Qamar, S., Alsayed, M., et al. (2023) · Dubai Diabetes and Endocrinology Journal · doi:10.1159/000530467 · Cited by 7
Association between marijuana use and kidney stone: a cross-sectional study of NHANES 2009 to 2018
Di, X., Xiang, L., Wang, M., & Wei, X. C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1214647 · Cited by 6
“1 mmol/L; e) diabetes medication or insulin history (Draznin et al., 2022).”
BackgroundManagement of Type 2 Diabetes Mellitus
Kawa, L. B. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002478 · Cited by 7
Exciting breakthroughs in the management of diabetes mellitus
Scheen, A. J. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100005 · Cited by 7
Fuzzy-Based Application Model and Profile Matching for Recommendation Suitability of Type 2 Diabetic
Wantoro, A., Syarif, A., Muludi, K., & Berawi, K. N. (2021) · International Journal on Advanced Science Engineering and Information Technology · doi:10.18517/ijaseit.11.3.12277 · Cited by 6
Zhang, P., Chen, M., Zhang, H., Luo, Y., Zhu, D., Li, X., Ji, J., Wang, D., Duolikun, N., & Ji, L. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00892-6 · Cited by 8
Atypical Diabetes and Management Considerations
Patil, S. P. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.003 · Cited by 6
Vencio, S. A. C., Vianna, A. G. D., da Silva, M. A. C. F., & Précoma, D. B. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00775-9 · Cited by 9
The cost of hypoglycemia associated with type 2 diabetes mellitus in taiwan
Strizek, A., Chang, C.-J., Furnback, W., Wang, B., Lebrec, J., & Lew, T. (2019) · Value in Health Regional Issues · doi:10.1016/j.vhri.2019.01.002 · Cited by 5
Gu, S., Gu, J., Wang, X., Wang, X., Li, L., Gu, H., & Xu, B. (2024) · Health Economics Review · doi:10.1186/s13561-024-00499-2 · Cited by 5
Builes-Montaño, C. E., Wandurraga-Sánchez, E. A., Ramírez, Á., & Ordóñez, J. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01471-9 · Cited by 5
Aroda, V. R., NIELSEN, N. F., Mangla, K. K., Multani, J. K., Divino, V. M., Namvar, T., & RAJPURA, J. R. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003825 · Cited by 8
Wang, T., Tao, T., Liu, Y., Dong, J., Ni, S., Liu, Y., Li, Y., Xu, N., & Sun, Z. (2024) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-024-00757-3 · Cited by 5
Metformin as an immunomodulatory agent in enhancing head and neck squamous cell carcinoma therapies
Li, W., Liu, N., Chen, M., Liu, D., & Liu, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189262 · Cited by 7
Fernandes, L. S., Braga, J. A. D. C., Cardoso, M. N., Squarcini, C. F. R., Campos, H. L. M., & de Leon, E. B. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251323780 · Cited by 5
Prevalence of Vitamin B12 Deficiency in Type 2 Diabetic Patients on Long-Term Metformin Therapy
Tayong, F. M., Francis, T. O., Jestin, K. J., Mahato, R. K., Ullah, H., Kamal, S., & Kamil, K. (2025) · Cureus · doi:10.7759/cureus.88265 · Cited by 5
Sidhu, S., Saseendrakumar, B. R., Varkhedi, V., Wu, J., Parikh, A. K., Nudleman, E., Jiun, L., Moghimi, S., Weinreb, R. N., & Baxter, S. L. (2025) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2024-002027 · Cited by 5
“37 For instance, in patients with type 2 diabetes who have or are at high risk for atherosclerotic cardiovascular disease, heart failure or chronic kidney disease, SGLT2 inhibitors and GLP-1 RAs are recommended with or without metformin.”
InfluentialScarberry, K. A., Thomas, G. M., Cowper, M. G., Chouhan, J. D., Thakker, P. U., Matz, E., Dutta, R., & Terlecki, R. P. (2020) · Urology · doi:10.1016/j.urology.2020.09.004 · Cited by 6
Warden, B. A., Steiner, J., Camacho, A., Nguyen, K. A., Purnell, J. Q., Duell, P. B., Craigan, C., Osborn, D., & Fazio, S. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100183 · Cited by 6
Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes
Le, P. N. B., Bui, T. C., Abramowitz, J., Herman, W. H., Misra‐Hebert, A. D., & Rothberg, M. B. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07621-2 · Cited by 6
Prescription medication use of United States military service members by therapeutic classification
Knapik, J. J., Trone, D. W., Steelman, R. A., Farina, E. K., & Lieberman, H. R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.972031 · Cited by 5
“Prescription medications (PMs) are provided to patients for treatment of specific medical conditions and are considered important components of treatment guidelines for many types of medical disorders (APA, 2019; Grundy et al., 2019; Unger et al., 2020; ADA, 2022).”
BackgroundKim, B., Huh, K. Y., Hwang, J. G., Nah, J. J., Huh, W., Cho, J. M., Jang, I., Yu, K., Kim, Y., & Lee, S. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15613 · Cited by 5
Impact of pharmacist intervention to improve medication access for patients with diabetes
Bias, A. A., Hiday, R. A., & Kline, M. M. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.12.021 · Cited by 5
Bando, H., Yamashita, H., Kato, Y., Kawata, T., Kato, Y., & Kanagawa, H. (2022) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2022/asjbccr.6278 · Cited by 7
Chanawong, A., Uitrakul, S., Incomenoy, S., & Poonchuay, N. (2023) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2023/5581417 · Cited by 8
Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review
Valencia-Morales, N. D., Cubillo, B. R., Loayza-López, R. K., de la Higuera, M. Á. M., & Sánchez-Fructuoso, A. I. (2023) · Life · doi:10.3390/life13061265 · Cited by 7
Wang, C., Ho, L., Wu, M., Wu, C., Tay, J., Su, P., Tsai, M., Wu, Y., Chang, W., Huang, C., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02403-8 · Cited by 5
“According to the current American Diabetes Association guidelines [41], the effect of metformin on HF is considered neutral, and metformin is considered to be the first-line antidiabetic medication in all patients with type 2 diabetes, including those with HF.”
Aldahmani, K. M., Suliman, M., Hafidh, K., & Beshyah, S. (2024) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0044-1786013 · Cited by 7
“33,40 Traditionally, fi rst-line therapy starts with metformin and comprehensive lifestyle modi fi cation.”
BackgroundLussier, M. E., Desai, R. J., Wright, E. A., & Gionfriddo, M. R. (2024) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2024.04.013 · Cited by 5
Joshi, N., Qasim, M. Z., Kanumilli, S., Shaukat, F., Kumar, A., Mahek, F., Khalid, S., Zeeshan, M., Shaik, M. Y., Nishat, S. M., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002494 · Cited by 6
“GLP1-RAs have been recommended by the American College of Cardiology (ACC) [60] , the European Society of Cardiology (ESC) [10] , and the American Diabetes Association (ADA) [61] for use in treatment regimens aimed at reducing ASCVD in high-risk patients with T2D.”
BackgroundComparative risk of infection of medications used for type 2 diabetes
Zapata-Bravo, E., Douros, A., Yu, O. H. Y., & Filion, K. B. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2401024 · Cited by 5
da Silva, J. G. M., de Melo, I. M. F., Alves, É. R., de Oliveira, G. M., da Silva, A. A., Pinto, F. C. M., Aguiar, J. L. D. A., Araújo, D. N., Teixeira, V. W., & Teixeira, Á. A. C. (2024) · Acta Cirúrgica Brasileira · doi:10.1590/acb399024 · Cited by 5
Joshi, N., Baloch, K. M., Rukh, S., Khan, A. M., Muskan, F., Kumari, V., Khan, H., Zeeshan, M., Azam, G., Khalid, S., et al. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002712 · Cited by 6
“Although GLP-1 RAs are neither FDA-approved nor of fi cially recommended in the management of type 1 diabetes [111,112] , off-label use added to insulin might contribute to weight reduction and better glycemic control in a subset.”
Abitbol, A., & Chu, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16278 · Cited by 5
Mao, Q., Zhang, X., Zhu, X., Tian, X., & Kong, Y. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.03.013 · Cited by 5
Lee, S. J., Ha, K. H., Lee, J. H., Lee, H., Kim, D. J., & Kim, H. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211959 · Cited by 5
Bando, H., Ebe, K., Muneta, T., Bando, M., & Yonei, Y. (2018) · Clinical Case Reports Open Access · doi:10.46527/2582-5038.103 · Cited by 8
Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis
Esteban, J. P., & Asgharpour, A. (2020) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.10.003 · Cited by 5
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 8
Intersection Between Diabetes and Heart Failure: Is SGLT2i the “One Stone for Two Birds” Approach?
Zhang, Q., Kang, Y., Tang, S., & Yu, C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01591-3 · Cited by 6
Polypharmacy in diabetes: A nation-wide, pharmacy-based, observational study
Larger, É., Alexandre‐Heymann, L., Pilet, S., Raoul, T., Perray, L., & Maravic, M. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100088 · Cited by 6
Cowart, K., Vascimini, A., Kumar, A., Tsalatsanis, A., Saba, Y., & Carris, N. W. (2022) · Clinical Diabetes · doi:10.2337/cd22-0046 · Cited by 5
Tsai, K.-Y., Chen, S. L., Chou, C., Tzeng, T., Lee, Y., & Chen, M. (2022) · PeerJ · doi:10.7717/peerj.13636 · Cited by 6
The treatment of diabetes in advanced liver disease: change of a paradigm
Petroni, M. L., Brodosi, L., & Marchesini, G. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100772 · Cited by 5
“After decades of stagnation, novel drugs, adding bene fi cial pleiotropic effects to their glucose lowering activity (Table 1), entered the market and totally replaced the old drugs in treatment diagrams proposed by international societies [1].”
BackgroundCHANDRAN, S. R., Tan, H. C., Chen, Q., Lee, P. C., Gardner, D. S.-L., Chin, Y. A., Lam, A. Y. R., Teh, M. M., & Bee, Y. M. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231157387 · Cited by 5
Urakami, T. (2023) · Clinical Pediatric Endocrinology · doi:10.1297/cpe.2023-0007 · Cited by 6
Ramadhani, P. F., Fauziah, F., & Kurnia, N. M. (2023) · International Journal of Pharmaceutical Sciences and Medicine · doi:10.47760/ijpsm.2023.v08i05.001 · Cited by 5
Thewjitcharoen, Y., Yenseung, N., Butadej, S., Nakasatien, S., Chotwanvirat, P., Chatchomchuan, W., Wanothayaroj, E., Krittiyawong, S., & Himathongkam, T. (2023) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.038.01.11 · Cited by 5
Zamanillo‐Campos, R., Dezcallar, M. Z., Moreiro, M. A. B., Leiva, A., Ripoll, J., Konieczna, J., Fiol-deRoque, M. A., & Ricci‐Cabello, I. (2023) · European Journal of General Practice · doi:10.1080/13814788.2023.2268838 · Cited by 6
Kumar, S. (2023) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_2114_22 · Cited by 6
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S125-S143
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200161106
- Cited by
- 1,555
- References
- 106
- Citations by year
- 2026: 42 · 2025: 132 · 2024: 219 · 2023: 393 · 2022: 403 · 2021: 153
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- glycemic control, pharmacotherapy, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.